Skip to main content
Top
Published in: Breast Cancer Research 5/2009

Open Access 01-10-2009 | Research article

Magnetic resonance imaging of the natural history of in situmammary neoplasia in transgenic mice: a pilot study

Authors: Sanaz A Jansen, Suzanne D Conzen, Xiaobing Fan, Erica J Markiewicz, Gillian M Newstead, Gregory S Karczmar

Published in: Breast Cancer Research | Issue 5/2009

Login to get access

Abstract

Introduction

Because of the small size of in situ mammary cancers in mouse models, high-resolution imaging techniques are required to effectively observe how lesions develop, grow and progress over time. The purpose of this study was to use magnetic resonance (MR) imaging to track in vivo the transition from in situ neoplasia to invasive cancer in a transgenic mouse model of human cancer.

Methods

MR images of 12 female C3(1) SV40 Tag mice that develop mammary intraepithelial neoplasia (MIN) were obtained. MIN is believed to be similar to human ductal carcinoma in situ (DCIS) and is considered a precursor of invasive tumors. Images were serially obtained from 10-21 weeks of age at 2-3 week intervals. MIN lesions were identified based on their morphology on MR images. Lesions were followed over time and several lesion features were measured including volume, growth rate and morphology. For those MIN lesions that progressed to invasive cancer the progression time was measured.

Results

Overall, 21 MIN lesions were initially detected at an average initial volume of 0.3 ± 0.2 mm3 with an average growth rate of -0.15 ± 0.66 week-1. Even though all mice were inbred to express the SV40 Tag transgene in the mammary epithelium and expected to develop invasive carcinoma, the individual MIN lesions took vastly different progression paths: (i) 9 lesions progressed to invasive tumors with an average progression time of 4.6 ± 1.9 weeks; (ii) 2 lesions regressed, i.e., were not detected on future images; and (iii) 5 were stable for over 8 weeks, and were demonstrated by a statistical model to represent indolent disease.

Conclusions

To our knowledge, the results reported here are the first measurements of the timescale and characteristics of progression from in situ neoplasia to invasive carcinoma and provide image-based evidence that DCIS may be a non-obligate precursor lesion with highly variable outcomes. In addition, this study represents a first step towards developing methods of image acquisition for identifying radiological characteristics that might predict which in situ neoplasias will become invasive cancers and which are unlikely to progress.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C: Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996, 275: 913-918. 10.1001/jama.275.12.913.CrossRefPubMed Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C: Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996, 275: 913-918. 10.1001/jama.275.12.913.CrossRefPubMed
2.
go back to reference Thomson JZ, Evans AJ, Pinder SE, Burrell HC, Wilson AR, Ellis IO: Growth pattern of ductal carcinoma in situ (DCIS): a retrospective analysis based on mammographic findings. Br J Cancer. 2001, 85: 225-227. 10.1054/bjoc.2001.1877.CrossRefPubMedPubMedCentral Thomson JZ, Evans AJ, Pinder SE, Burrell HC, Wilson AR, Ellis IO: Growth pattern of ductal carcinoma in situ (DCIS): a retrospective analysis based on mammographic findings. Br J Cancer. 2001, 85: 225-227. 10.1054/bjoc.2001.1877.CrossRefPubMedPubMedCentral
3.
go back to reference Sanders ME, Schuyler PA, Dupont WD, Page DL: The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005, 103: 2481-2484. 10.1002/cncr.21069.CrossRefPubMed Sanders ME, Schuyler PA, Dupont WD, Page DL: The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005, 103: 2481-2484. 10.1002/cncr.21069.CrossRefPubMed
4.
go back to reference Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ: Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer. 2005, 103: 1778-1784. 10.1002/cncr.20979.CrossRefPubMed Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ: Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer. 2005, 103: 1778-1784. 10.1002/cncr.20979.CrossRefPubMed
5.
go back to reference Erbas B, Provenzano E, Armes J, Gertig D: The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006, 97: 135-144. 10.1007/s10549-005-9101-z.CrossRefPubMed Erbas B, Provenzano E, Armes J, Gertig D: The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006, 97: 135-144. 10.1007/s10549-005-9101-z.CrossRefPubMed
6.
go back to reference Duffy SW, Agbaje O, Tabar L, Vitak B, Bjurstam N, Bjorneld L, Myles JP, Warwick J: Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res. 2005, 7: 258-265. 10.1186/bcr1354.CrossRefPubMedPubMedCentral Duffy SW, Agbaje O, Tabar L, Vitak B, Bjurstam N, Bjorneld L, Myles JP, Warwick J: Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res. 2005, 7: 258-265. 10.1186/bcr1354.CrossRefPubMedPubMedCentral
7.
go back to reference Duffy SW, Tabar L, Vitak B, Day NE, Smith RA, Chen HH, Yen MF: The relative contributions of screen-detected in situ and invasive breast carcinomas in reducing mortality from the disease. Eur J Cancer. 2003, 39: 1755-1760. 10.1016/S0959-8049(03)00259-4.CrossRefPubMed Duffy SW, Tabar L, Vitak B, Day NE, Smith RA, Chen HH, Yen MF: The relative contributions of screen-detected in situ and invasive breast carcinomas in reducing mortality from the disease. Eur J Cancer. 2003, 39: 1755-1760. 10.1016/S0959-8049(03)00259-4.CrossRefPubMed
8.
go back to reference Yen MF, Tabar L, Vitak B, Smith RA, Chen HH, Duffy SW: Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer. 2003, 39: 1746-1754. 10.1016/S0959-8049(03)00260-0.CrossRefPubMed Yen MF, Tabar L, Vitak B, Smith RA, Chen HH, Duffy SW: Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer. 2003, 39: 1746-1754. 10.1016/S0959-8049(03)00260-0.CrossRefPubMed
9.
go back to reference Kerlikowske K, Molinaro A, Cha I, Ljung BM, Ernster VL, Stewart K, Chew K, Moore DH, Waldman F: Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst. 2003, 95: 1692-1702.CrossRefPubMed Kerlikowske K, Molinaro A, Cha I, Ljung BM, Ernster VL, Stewart K, Chew K, Moore DH, Waldman F: Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst. 2003, 95: 1692-1702.CrossRefPubMed
10.
go back to reference Jansen SA, Conzen SD, Fan X, Krausz T, Zamora M, Foxley S, River J, Newstead GM, Karczmar GS: Detection of in situ mammary cancer in a transgenic mouse model: in vitro and in vivo MRI studies demonstrate histopathologic correlation. Phys Med Biol. 2008, 53: 5481-5493. 10.1088/0031-9155/53/19/014.CrossRefPubMedPubMedCentral Jansen SA, Conzen SD, Fan X, Krausz T, Zamora M, Foxley S, River J, Newstead GM, Karczmar GS: Detection of in situ mammary cancer in a transgenic mouse model: in vitro and in vivo MRI studies demonstrate histopathologic correlation. Phys Med Biol. 2008, 53: 5481-5493. 10.1088/0031-9155/53/19/014.CrossRefPubMedPubMedCentral
11.
go back to reference Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE: The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene. 2000, 19: 968-988. 10.1038/sj.onc.1203277.CrossRefPubMed Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE: The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene. 2000, 19: 968-988. 10.1038/sj.onc.1203277.CrossRefPubMed
12.
go back to reference Maroulakou IG, Anver M, Garrett L, Green JE: Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA. 1994, 91: 11236-11240. 10.1073/pnas.91.23.11236.CrossRefPubMedPubMedCentral Maroulakou IG, Anver M, Garrett L, Green JE: Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA. 1994, 91: 11236-11240. 10.1073/pnas.91.23.11236.CrossRefPubMedPubMedCentral
13.
go back to reference Fan X, Markiewicz EJ, Zamora M, Karczmar GS, Roman BB: Comparison and evaluation of mouse cardiac MRI acquired with open birdcage, single loop surface and volume birdcage coils. Phys Med Biol. 2006, 51: N451-459. 10.1088/0031-9155/51/24/N01.CrossRefPubMed Fan X, Markiewicz EJ, Zamora M, Karczmar GS, Roman BB: Comparison and evaluation of mouse cardiac MRI acquired with open birdcage, single loop surface and volume birdcage coils. Phys Med Biol. 2006, 51: N451-459. 10.1088/0031-9155/51/24/N01.CrossRefPubMed
14.
go back to reference ACR: American College of Radiology (ACR) Breast Imaging Reporting and Data System Atlas (BI-RADS). 2003, Reston, VA; American College of Radiology ACR: American College of Radiology (ACR) Breast Imaging Reporting and Data System Atlas (BI-RADS). 2003, Reston, VA; American College of Radiology
15.
go back to reference Abbey CK, Borowsky AD, Gregg JP, Cardiff RD, Cherry SR: Preclinical imaging of mammary intraepithelial neoplasia with positron emission tomography. J Mammary Gland Biol Neoplasia. 2006, 11: 137-149. 10.1007/s10911-006-9020-6.CrossRefPubMed Abbey CK, Borowsky AD, Gregg JP, Cardiff RD, Cherry SR: Preclinical imaging of mammary intraepithelial neoplasia with positron emission tomography. J Mammary Gland Biol Neoplasia. 2006, 11: 137-149. 10.1007/s10911-006-9020-6.CrossRefPubMed
16.
go back to reference Abbey CK, Borowsky AD, McGoldrick ET, Gregg JP, Maglione JE, Cardiff RD, Cherry SR: In vivo positron-emission tomography imaging of progression and transformation in a mouse model of mammary neoplasia. Proc Natl Acad Sci USA. 2004, 101: 11438-11443. 10.1073/pnas.0404396101.CrossRefPubMedPubMedCentral Abbey CK, Borowsky AD, McGoldrick ET, Gregg JP, Maglione JE, Cardiff RD, Cherry SR: In vivo positron-emission tomography imaging of progression and transformation in a mouse model of mammary neoplasia. Proc Natl Acad Sci USA. 2004, 101: 11438-11443. 10.1073/pnas.0404396101.CrossRefPubMedPubMedCentral
17.
go back to reference Verschoyle RD, Brown K, Steward WP, Gescher AJ: Consumption of silibinin, a flavonolignan from milk thistle, and mammary cancer development in the C3(1) SV40 T, t antigen transgenic multiple mammary adenocarcinoma (TAg) mouse. Cancer Chemother Pharmacol. 2008, 62: 369-372. 10.1007/s00280-007-0611-8.CrossRefPubMed Verschoyle RD, Brown K, Steward WP, Gescher AJ: Consumption of silibinin, a flavonolignan from milk thistle, and mammary cancer development in the C3(1) SV40 T, t antigen transgenic multiple mammary adenocarcinoma (TAg) mouse. Cancer Chemother Pharmacol. 2008, 62: 369-372. 10.1007/s00280-007-0611-8.CrossRefPubMed
18.
go back to reference Leong H, Mathur PS, Greene GL: Inhibition of mammary tumorigenesis in the C3(1)/SV40 mouse model by green tea. Breast Cancer Res Treat. 2008, 107: 359-369. 10.1007/s10549-007-9568-x.CrossRefPubMed Leong H, Mathur PS, Greene GL: Inhibition of mammary tumorigenesis in the C3(1)/SV40 mouse model by green tea. Breast Cancer Res Treat. 2008, 107: 359-369. 10.1007/s10549-007-9568-x.CrossRefPubMed
19.
go back to reference Kaur S, Greaves P, Cooke DN, Edwards R, Steward WP, Gescher AJ, Marczylo TH: Breast cancer prevention by green tea catechins and black tea theaflavins in the C3(1) SV40 T, t antigen transgenic mouse model is accompanied by increased apoptosis and a decrease in oxidative DNA adducts. J Agric Food Chem. 2007, 55: 3378-3385. 10.1021/jf0633342.CrossRefPubMed Kaur S, Greaves P, Cooke DN, Edwards R, Steward WP, Gescher AJ, Marczylo TH: Breast cancer prevention by green tea catechins and black tea theaflavins in the C3(1) SV40 T, t antigen transgenic mouse model is accompanied by increased apoptosis and a decrease in oxidative DNA adducts. J Agric Food Chem. 2007, 55: 3378-3385. 10.1021/jf0633342.CrossRefPubMed
20.
go back to reference Liu R, Varghese S, Rabkin SD: Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. Cancer Res. 2005, 65: 1532-1540. 10.1158/0008-5472.CAN-04-3353.CrossRefPubMed Liu R, Varghese S, Rabkin SD: Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. Cancer Res. 2005, 65: 1532-1540. 10.1158/0008-5472.CAN-04-3353.CrossRefPubMed
21.
go back to reference Wild R, Yokoyama Y, Dings RP, Ramakrishnan S: VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis. Breast Cancer Res Treat. 2004, 85: 161-171. 10.1023/B:BREA.0000025407.02896.ec.CrossRefPubMed Wild R, Yokoyama Y, Dings RP, Ramakrishnan S: VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis. Breast Cancer Res Treat. 2004, 85: 161-171. 10.1023/B:BREA.0000025407.02896.ec.CrossRefPubMed
22.
go back to reference Wu Y, Cui K, Miyoshi K, Hennighausen L, Green JE, Setser J, LeRoith D, Yakar S: Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res. 2003, 63: 4384-4388.PubMed Wu Y, Cui K, Miyoshi K, Hennighausen L, Green JE, Setser J, LeRoith D, Yakar S: Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res. 2003, 63: 4384-4388.PubMed
23.
go back to reference Kavanaugh C, Green JE: The use of genetically altered mice for breast cancer prevention studies. J Nutr. 2003, 133: 2404S-2409S.PubMed Kavanaugh C, Green JE: The use of genetically altered mice for breast cancer prevention studies. J Nutr. 2003, 133: 2404S-2409S.PubMed
24.
go back to reference Shibata MA, Kavanaugh C, Shibata E, Abe H, Nguyen P, Otsuki Y, Trepel JB, Green JE: Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis. 2003, 24: 453-459. 10.1093/carcin/24.3.453.CrossRefPubMed Shibata MA, Kavanaugh C, Shibata E, Abe H, Nguyen P, Otsuki Y, Trepel JB, Green JE: Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis. 2003, 24: 453-459. 10.1093/carcin/24.3.453.CrossRefPubMed
25.
go back to reference Calvo A, Yokoyama Y, Smith LE, Ali I, Shih SC, Feldman AL, Libutti SK, Sundaram R, Green JE: Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer. 2002, 101: 224-234. 10.1002/ijc.10589.CrossRefPubMed Calvo A, Yokoyama Y, Smith LE, Ali I, Shih SC, Feldman AL, Libutti SK, Sundaram R, Green JE: Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer. 2002, 101: 224-234. 10.1002/ijc.10589.CrossRefPubMed
26.
go back to reference Calvo A, Feldman AL, Libutti SK, Green JE: Adenovirus-mediated endostatin delivery results in inhibition of mammary gland tumor growth in C3(1)/SV40 T-antigen transgenic mice. Cancer Res. 2002, 62: 3934-3938.PubMed Calvo A, Feldman AL, Libutti SK, Green JE: Adenovirus-mediated endostatin delivery results in inhibition of mammary gland tumor growth in C3(1)/SV40 T-antigen transgenic mice. Cancer Res. 2002, 62: 3934-3938.PubMed
27.
go back to reference Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, Brown PH: Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev. 2002, 11: 467-474.PubMed Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, Brown PH: Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev. 2002, 11: 467-474.PubMed
28.
go back to reference Green JE, Shibata MA, Shibata E, Moon RC, Anver MR, Kelloff G, Lubet R: 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Cancer Res. 2001, 61: 7449-7455.PubMed Green JE, Shibata MA, Shibata E, Moon RC, Anver MR, Kelloff G, Lubet R: 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Cancer Res. 2001, 61: 7449-7455.PubMed
29.
go back to reference Shibata MA, Yoshidome K, Shibata E, Jorcyk CL, Green JE: Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Ther. 2001, 8: 23-35. 10.1038/sj.cgt.7700275.CrossRefPubMed Shibata MA, Yoshidome K, Shibata E, Jorcyk CL, Green JE: Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Ther. 2001, 8: 23-35. 10.1038/sj.cgt.7700275.CrossRefPubMed
30.
go back to reference Wu K, Kim HT, Rodriquez JL, Munoz-Medellin D, Mohsin SK, Hilsenbeck SG, Lamph WW, Gottardis MM, Shirley MA, Kuhn JG, Green JE, Brown PH: 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin Cancer Res. 2000, 6: 3696-3704.PubMed Wu K, Kim HT, Rodriquez JL, Munoz-Medellin D, Mohsin SK, Hilsenbeck SG, Lamph WW, Gottardis MM, Shirley MA, Kuhn JG, Green JE, Brown PH: 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin Cancer Res. 2000, 6: 3696-3704.PubMed
31.
go back to reference Holzer RG, MacDougall C, Cortright G, Atwood K, Green JE, Jorcyk CL: Development and characterization of a progressive series of mammary adenocarcinoma cell lines derived from the C3(1)/SV40 Large T-antigen transgenic mouse model. Breast Cancer Res Treat. 2003, 77: 65-76. 10.1023/A:1021175931177.CrossRefPubMed Holzer RG, MacDougall C, Cortright G, Atwood K, Green JE, Jorcyk CL: Development and characterization of a progressive series of mammary adenocarcinoma cell lines derived from the C3(1)/SV40 Large T-antigen transgenic mouse model. Breast Cancer Res Treat. 2003, 77: 65-76. 10.1023/A:1021175931177.CrossRefPubMed
32.
go back to reference Yoshidome K, Shibata MA, Couldrey C, Korach KS, Green JE: Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression. Cancer Res. 2000, 60: 6901-6910.PubMed Yoshidome K, Shibata MA, Couldrey C, Korach KS, Green JE: Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression. Cancer Res. 2000, 60: 6901-6910.PubMed
33.
go back to reference Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, Wigginton J, Wiltrout R, Shibata E, Kaczmarczyk S, Wang W, Liu ZY, Calvo A, Couldrey C: The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene. 2000, 19: 1020-1027. 10.1038/sj.onc.1203280.CrossRefPubMed Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, Wigginton J, Wiltrout R, Shibata E, Kaczmarczyk S, Wang W, Liu ZY, Calvo A, Couldrey C: The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene. 2000, 19: 1020-1027. 10.1038/sj.onc.1203280.CrossRefPubMed
34.
go back to reference Liu ML, Von Lintig FC, Liyanage M, Shibata MA, Jorcyk CL, Ried T, Boss GR, Green JE: Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice. Oncogene. 1998, 17: 2403-2411. 10.1038/sj.onc.1202456.CrossRefPubMed Liu ML, Von Lintig FC, Liyanage M, Shibata MA, Jorcyk CL, Ried T, Boss GR, Green JE: Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice. Oncogene. 1998, 17: 2403-2411. 10.1038/sj.onc.1202456.CrossRefPubMed
35.
go back to reference Yoshidome K, Shibata MA, Maroulakou IG, Liu ML, Jorcyk CL, Gold LG, Welch VN, Green JE: Genetic alterations in the development of mammary and prostate cancer in the C3(1)/Tag transgenic mouse model. Int J Oncol. 1998, 12: 449-453.PubMed Yoshidome K, Shibata MA, Maroulakou IG, Liu ML, Jorcyk CL, Gold LG, Welch VN, Green JE: Genetic alterations in the development of mammary and prostate cancer in the C3(1)/Tag transgenic mouse model. Int J Oncol. 1998, 12: 449-453.PubMed
36.
go back to reference Shibata MA, Maroulakou IG, Jorcyk CL, Gold LG, Ward JM, Green JE: p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. Cancer Res. 1996, 56: 2998-3003.PubMed Shibata MA, Maroulakou IG, Jorcyk CL, Gold LG, Ward JM, Green JE: p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. Cancer Res. 1996, 56: 2998-3003.PubMed
37.
go back to reference Zahl PH, Maehlen J, Welch HG: The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med. 2008, 168: 2311-2316. 10.1001/archinte.168.21.2311.CrossRefPubMed Zahl PH, Maehlen J, Welch HG: The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med. 2008, 168: 2311-2316. 10.1001/archinte.168.21.2311.CrossRefPubMed
38.
go back to reference Krutchik AN, Buzdar AU, Blumenschein GR, Lukeman JM: Spontaneous regression of breast carcinoma. Arch Intern Med. 1978, 138: 1734-1735. 10.1001/archinte.138.11.1734.CrossRefPubMed Krutchik AN, Buzdar AU, Blumenschein GR, Lukeman JM: Spontaneous regression of breast carcinoma. Arch Intern Med. 1978, 138: 1734-1735. 10.1001/archinte.138.11.1734.CrossRefPubMed
39.
go back to reference Dussan C, Zubor P, Fernandez M, Yabar A, Szunyogh N, Visnovsky J: Spontaneous regression of a breast carcinoma: a case report. Gynecol Obstet Invest. 2008, 65: 206-211. 10.1159/000112228.CrossRefPubMed Dussan C, Zubor P, Fernandez M, Yabar A, Szunyogh N, Visnovsky J: Spontaneous regression of a breast carcinoma: a case report. Gynecol Obstet Invest. 2008, 65: 206-211. 10.1159/000112228.CrossRefPubMed
40.
41.
go back to reference Franks SJ, Byrne HM, Underwood JC, Lewis CE: Biological inferences from a mathematical model of comedo ductal carcinoma in situ of the breast. J Theor Biol. 2005, 232: 523-543. 10.1016/j.jtbi.2004.08.032.CrossRefPubMed Franks SJ, Byrne HM, Underwood JC, Lewis CE: Biological inferences from a mathematical model of comedo ductal carcinoma in situ of the breast. J Theor Biol. 2005, 232: 523-543. 10.1016/j.jtbi.2004.08.032.CrossRefPubMed
42.
go back to reference Franks SJ, Byrne HM, Mudhar HS, Underwood JC, Lewis CE: Mathematical modelling of comedo ductal carcinoma in situ of the breast. Math Med Biol. 2003, 20: 277-308. 10.1093/imammb/20.3.277.CrossRefPubMed Franks SJ, Byrne HM, Mudhar HS, Underwood JC, Lewis CE: Mathematical modelling of comedo ductal carcinoma in situ of the breast. Math Med Biol. 2003, 20: 277-308. 10.1093/imammb/20.3.277.CrossRefPubMed
43.
go back to reference Franks SJ, Byrne HM, King JR, Underwood JC, Lewis CE: Modelling the early growth of ductal carcinoma in situ of the breast. J Math Biol. 2003, 47: 424-452. 10.1007/s00285-003-0214-x.CrossRefPubMed Franks SJ, Byrne HM, King JR, Underwood JC, Lewis CE: Modelling the early growth of ductal carcinoma in situ of the breast. J Math Biol. 2003, 47: 424-452. 10.1007/s00285-003-0214-x.CrossRefPubMed
44.
go back to reference Tabar L, Tony Chen HH, Amy Yen MF, Tot T, Tung TH, Chen LS, Chiu YH, Duffy SW, Smith RA: Mammographic tumor features can predict long-term outcomes reliably in women with 1-14-mm invasive breast carcinoma. Cancer. 2004, 101: 1745-1759. 10.1002/cncr.20582.CrossRefPubMed Tabar L, Tony Chen HH, Amy Yen MF, Tot T, Tung TH, Chen LS, Chiu YH, Duffy SW, Smith RA: Mammographic tumor features can predict long-term outcomes reliably in women with 1-14-mm invasive breast carcinoma. Cancer. 2004, 101: 1745-1759. 10.1002/cncr.20582.CrossRefPubMed
45.
go back to reference Tabar L, Chen HH, Duffy SW, Yen MF, Chiang CF, Dean PB, Smith RA: A novel method for prediction of long-term outcome of women with T1a, T1b, and 10-14 mm invasive breast cancers: a prospective study. Lancet. 2000, 355: 429-433.CrossRefPubMed Tabar L, Chen HH, Duffy SW, Yen MF, Chiang CF, Dean PB, Smith RA: A novel method for prediction of long-term outcome of women with T1a, T1b, and 10-14 mm invasive breast cancers: a prospective study. Lancet. 2000, 355: 429-433.CrossRefPubMed
46.
go back to reference Jansen SA, Paunesku T, Fan X, Woloschak GE, Vogt S, Krausz T, Conzen SD, Newstead GM, Karczmar GS: X-ray fluorescence microscopy and DCEMRI of murine ductal carcinoma in situ reveals gadolinium uptake within neoplastic mammary ducts. Radiology. 2009, Jansen SA, Paunesku T, Fan X, Woloschak GE, Vogt S, Krausz T, Conzen SD, Newstead GM, Karczmar GS: X-ray fluorescence microscopy and DCEMRI of murine ductal carcinoma in situ reveals gadolinium uptake within neoplastic mammary ducts. Radiology. 2009,
Metadata
Title
Magnetic resonance imaging of the natural history of in situmammary neoplasia in transgenic mice: a pilot study
Authors
Sanaz A Jansen
Suzanne D Conzen
Xiaobing Fan
Erica J Markiewicz
Gillian M Newstead
Gregory S Karczmar
Publication date
01-10-2009
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2009
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2357

Other articles of this Issue 5/2009

Breast Cancer Research 5/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine